ICCM Q3'26 Earnings: EPS estimate is (1.16) USD
ICCM (IceCure Medical Ltd.) will release Q3'26 earnings on November 18. Analysts expect revenue of 876.50 thousand USD and an EPS of (1.16) USD. The announcement is scheduled for 7:30 AM ET (12:30 PM UTC).
How this was made

The 30-second read
Why it matters
The main trading relevance is timing and the direction implied by negative consensus EPS, which can influence positioning into the print.
Market read
This is a pre-earnings setup for ICCM with consensus EPS of -1.16 and revenue of $876.5k, likely to drive near-term volatility around the release.
What to watch
For micro/small-cap biotech, investors often react to cash runway, trial or regulatory updates, and management commentary; none of those details are included here.
Background
The article frames ICCM’s upcoming Q3'26 earnings release date and consensus estimates for revenue and EPS.
Ticker impact
ICCM is scheduled to report Q3'26 results Nov. 18 pre-market, with consensus EPS expected at -1.16 and revenue at $876.5k.
Potential volatility around whether reported EPS and revenue come in better or worse than the -1.16 EPS and $876.5k revenue expectations.
The article provides the upcoming earnings timing and consensus estimates, which can drive pre-earnings positioning and post-print repricing if results deviate.
Market effects
Limited read-through to the broader biotech/medical-device space because the article is a single-company earnings setup with small absolute revenue.
Minimal, as the catalyst is company-specific and not a macro release.
Low, since the disclosure is not tied to global policy, commodities, or cross-market flows.
Counterpoint
Because the piece is only a scheduled earnings preview with consensus numbers, price action may be driven more by guidance or cash-burn commentary than by the headline EPS/revenue estimates.
Key entities
- companyICCM
IceCure Medical Ltd., scheduled to report Q3'26 results on Nov. 18 before market open.

